Alzamend Neuro closed at $1.46 on Nov 3, up 16.80%, 42.7% below its 52-week closing high. Volume of 241.2K shares was 13.17× its 20-day average (well above normal).
Split-adjusted performance: +3.5% over one month, +36.4% over six months, -42.3% over one year.
Short interest was 34.2K shares at the Oct 15 settlement, down 69.4% from the prior report (0.7% of float, 1.0 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −26.5%, revenue growth +6.4%, net margin −38.1%, P/E 16.4×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| ALZNAlzamend Neuro | $1.46 | +16.80% | +36.4% | — | — | — | $7.0M | |
| FBLGFibroBiologics | $0.9900 | +7.60% | −25.6% | — | — | — | $7.0M | Compare |
| ENSCEnsysce Biosciences | $0.3777 | −1.15% | −5.6% | −15.1% | −220.8% | — | $7.3M | Compare |
| ENVBEnveric Biosciences | $1.50 | +3.45% | −56.9% | — | — | — | $6.7M | Compare |
| VTGNVistagen Therapeutics | $0.1680 | +0.30% | −72.0% | +504.9% | −882.8% | — | $7.5M | Compare |
| CNSPCNS Pharmaceuticals | $4.55 | +3.64% | −36.4% | — | — | — | $6.6M | Compare |
| NAIINatural Alternatives International | $1.06 | −0.93% | −59.4% | +1.9% | −39.2% | — | $6.6M | Compare |
| XCURExicure | $1.01 | −0.98% | −70.3% | — | — | — | $6.6M | Compare |
| KPRXKiora Pharmaceuticals | $1.73 | +6.13% | −31.1% | — | — | — | $7.7M | Compare |
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's disease. The Company has two therapeutic drug candidates, AL001 and ALZN002. Its pipeline consists of AL001, a patented ionic cocrystal technology delivering lithium through a therapeutic combination of lithium, proline and salicylate; and ALZN002, a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's disease.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
